Actylis, a global manufacturer of raw materials and performance ingredients for the life sciences and specialty chemicals markets, has opened a new 30,000 square foot cGMP facility in Eugene, OR. The multi-million dollar construction commenced in February of 2021 and was completed in September of 2022, with commissioning and qualification completed at the end of January 2023.

“Today we are delighted to announce that this purpose-built 30,000 square foot facility has commenced operations, allowing us to develop and manufacture GMP APIs and pharma intermediates from clinical trial to commercial volumes,” said Gilles Cottier, CEO of Actylis. “We designed this facility specifically to enable us to develop and produce innovative APIs for our customers. We worked closely with architect firm BCA (Blaise Cacciola Architect) and Coffman Engineering to build a facility that has the most up-to-date technology and equipment available.”

Christine Bellmor, site director, elaborated on some of the specific capabilities of the site. “We are excited to have this state-of-the-art facility here in Eugene come online after such an intensive design and development process,” she said. “We have 7 manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3. We have a number of different reactors to allow flexibility for a variety of chemistries. Commissioning and qualifications for clinical GMP were completed at the end of January this year and we already have our first projects completed and more are underway. The new facility is a 10-minute drive from our R&D facility which is critical for scaling and developing new processes for the plant. We are very proud of the site and look forward to welcoming customers to the facility so that they can see for themselves the capabilities we offer.”

The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned. Along with the other GMP sites in Montreal (Canada), Limerick (Ireland) and Ahmedabad (India), Actylis has a presence in 10 countries spanning three continents and offers more than 4,500 products. Actylis’ capabilities encompass the entire R&D, product development and manufacturing spectrum, including technical sales support, R&D, manufacturing and production, quality, supply chain, global sourcing, and regulatory compliance.